Clinical Trial Update: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating the combination of bexarotene and GM-CSF in patients with myelodysplastic syndromes or acute myeloid leukemia has been compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Bexarotene (Bexarotene)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2018-09-05